Author:
Kondo Takayuki,Fujiwara Kisako,Nakagawa Miyuki,Fujimoto Kentaro,Yumita Sae,Ishino Takamasa,Ogawa Keita,Iwanaga Terunao,Koroki Keisuke,Kanzaki Hiroaki,Inoue Masanori,Kobayashi Kazufumi,Kiyono Soichiro,Nakamura Masato,Kanogawa Naoya,Ogasawara Sadahisa,Nakamoto Shingo,Chiba Tetsuhiro,Kato Jun,Kato Naoya
Abstract
AbstractThe effect of the combination of atezolizumab and bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC) on pulmonary arterial hypertension (PAH) is unknown. Estimation of PAH by using computed tomography (CT) has recently been proposed. Thus, we aimed to estimate the effect of Atez/Bev on PAH using CT. Altogether, 113 patients who received Atez/Bev for HCC were enrolled. Probable PAH was defined as the diameter of the main pulmonary artery (mPA-D) ≥ 33 mm, whereas suspicious PAH was defined as mPA-D ≥ 29 mm or mPA-D/the diameter of the ascending aorta (aAo-D) ≥ 1.0. Before treatment, probable/suspicious PAH were diagnosed in 7 (6.7%)/22 (21.0%) patients, respectively. mPA-D and mPA-D/aAo-D significantly increased after induction of Atez/Bev. The increment of mPA-D was correlated with the occurrence of post-treatment respiratory/heart failure. In analysis of 55 patients who underwent CT at 3 months after the last dose of Atez/Bev, mPA-D and mPA-D/aAo-D significantly decreased. However, in the group with continuous treatment of other molecular-targeted drugs after Atez/Bev, mPA-D and mPA-D/aAo-D showed no significant change. In conclusion, PAH may not be a rare complication in patients with HCC and should be managed carefully because of the possible negative effect of Atez/Bev on PAH.
Publisher
Springer Science and Business Media LLC